PT-141 Peptide Research: Benefits, Studies, and Evidence

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide researched as a melanocortin-receptor agonist with preferential activity at MC4R — the receptor subtype most closely tied to central regulation of sexual function. It is one of the rare research peptides to complete the full drug-development arc: discovered in a university laboratory, optimized by a biotech company, tested in large randomized trials, and approved by the FDA as the drug product Vyleesi in 2019.

Developed by Palatin Technologies from the melanocortin program that produced Melanotan II, bremelanotide was engineered for greater MC4R selectivity — narrowing MT-II’s broad receptor activity toward the receptor subtype behind the sexual-function findings. Its research history spans early male erectile-function studies and the large female sexual-dysfunction trial program.

Ver materiales de investigación: Tienda VONOX Labs

Research Use Only: Vonox Labs products are intended strictly for laboratory and research purposes and are not intended for human or veterinary consumption. This information is provided for educational purposes only and is not medical advice.

What Is PT-141?

PT-141 is the development code for bremelanotide, a cyclic seven-amino-acid peptide — Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH (molecular weight ~1,025 Da) — built on the same alpha-MSH-derived scaffold as Melanotan II. The two differ in key details: bremelanotide carries a free C-terminal acid where MT-II is amidated, and its receptor profile is shifted toward MC4R selectivity rather than MT-II’s broad four-receptor agonism.

The compound binds melanocortin receptors MC1R, MC3R, and MC4R, acting as an agonist with its highest affinity at MC4R. The literature uses both names: PT-141 in early studies, bremelanotide in later clinical work.

Research has investigated PT-141 for its relationship with central sexual-desire signaling, erectile response, female sexual dysfunction, and melanocortin-receptor pharmacology.

How Does PT-141 Work?

PT-141 has been studied as an agonist of the melanocortin receptors, with its sexual-function research attributed primarily to MC4R activation in central (brain) circuits. Researchers have investigated its relationship with:

• MC4R agonism in hypothalamic circuits — MC4R is densely expressed in hypothalamic nuclei involved in sexual motivation and arousal; this central action is the proposed basis for its effects on desire and erectile response alike
• Central vs. peripheral action — unlike PDE5 inhibitors (sildenafil and related drugs), which act peripherally on vascular smooth muscle, PT-141 acts upstream in the brain, initiating the arousal cascade centrally — a mechanistically distinct pathway documented in both animal and human studies
• Downstream monoamine modulation — investigators have described the mechanism as engaging alpha-MSH-like central signaling proposed to modulate dopamine and norepinephrine pathways involved in sexual motivation, distinct from the nitric-oxide/cGMP pathway of PDE5 inhibitors
• Selectivity contrast with MT-II — bremelanotide’s narrower MC4R-focused profile is the engineered difference from Melanotan II’s broad four-receptor agonism

Key Takeaway: PT-141 is particularly interesting to researchers because it represents the melanocortin system’s most complete translation story — a centrally acting MC4R agonist taken from receptor pharmacology to FDA-approved medicine — though the human evidence is concentrated in one narrow indication and the early male program never reached approval.

Potential Benefits of PT-141

Female Sexual Desire Research: The RECONNECT Trials

The largest PT-141 research is the RECONNECT program — two identical Phase 3, randomized, double-blind, placebo-controlled, multicenter trials of subcutaneous bremelanotide as needed in premenopausal women with hypoactive sexual desire disorder (HSDD).

Across the two trials, 1,267 women were randomized (1,247 safety, 1,202 modified intent-to-treat) to 24 weeks of bremelanotide or placebo. Coprimary endpoints were change in the FSFI desire-domain score and in distress related to low desire (FSDS-DAO item 13). Bremelanotide produced statistically significant increases in sexual desire (study 301: 0.30, P<.001; study 302: 0.42, P<.001; integrated 0.35, P<.001) and significant reductions in distress (301: −0.37, P<.001; 302: −0.29, P=.005; integrated −0.33, P<.001) versus placebo. The most common adverse events were nausea, flushing, and headache.

Notably, the absolute effect sizes were numerically modest despite statistical significance, and the population was narrow — mean age 39, 85.6% white, 96.6% US-based. The trials were preceded by a Phase 2b dose-finding study and followed by a 52-week open-label extension.

Male Erectile Function Research

PT-141’s earlier research life was in male erectile dysfunction via intranasal delivery. A double-blind, placebo-controlled study in healthy men and Viagra-responsive ED patients found a statistically significant erectile response versus placebo at doses above 7 mg, with first erection at approximately 30 minutes; flushing and nausea were the most common adverse events.

A subsequent study examined co-administration with sildenafil: 19 men with ED received sildenafil 25 mg alone versus sildenafil plus 7.5 mg intranasal PT-141, with the combination producing a significantly greater erectile response versus sildenafil alone.

The male program did not advance to an approved product; intranasal PT-141 for ED was discontinued after early-phase development.

Central Melanocortin Mechanism Research

Preclinical-to-clinical reviews traced the compound from hypothalamic MC4R pharmacology through human sexual-function studies, and animal research has investigated MC4R circuits in sexual motivation and arousal — establishing the melanocortin system as a brain-level regulator of sexual behavior.

It is important to distinguish these laboratory and trial findings from demonstrated outcomes beyond the studied populations and indications.

PT-141 vs. Other Peptides

Melanotan II is PT-141’s direct ancestor: the non-selective cyclic heptapeptide whose erectile-function research created the melanocortin sexual-medicine program. Bremelanotide is the engineered descendant — same scaffold, narrower MC4R-focused profile, and the only one of the two with an approved drug product. MT-II itself was never approved for any indication.

Vyleesi is the source of the most common confusion in PT-141 discussions: Vyleesi is bremelanotide — the FDA-approved drug product — but the approval covers a specific pharmaceutical formulation for a specific indication (acquired, generalized HSDD in premenopausal women). Research-use PT-141 material is not Vyleesi, and the approval says nothing about unregulated products.

PT-141 has a different research profile from peptides such as BPC-157, TB-500, and MOTS-c, which are researched for tissue repair and metabolic regulation rather than central receptor pharmacology. KPV shares the alpha-MSH lineage but acts independently of melanocortin receptors entirely — the opposite pharmacological story from the same parent hormone.

PT-141’s research is more closely associated with:

Melanocortin Receptor Agonism → Central MC4R Signaling → Sexual Desire & Arousal Circuits → Clinical Sexual-Medicine Research

What sets PT-141 apart is completion: few research peptides have traveled from receptor pharmacology through Phase 3 trials to an FDA-approved product.

Regulatory Status

PT-141’s regulatory position is unusual for a research peptide and must be stated precisely:

• Bremelanotide IS FDA approved — as the drug product Vyleesi, approved in June 2019 for acquired, generalized hypoactive sexual desire disorder in premenopausal women. This is a real, current FDA approval for a specific pharmaceutical product and indication.
• The approval does not extend to research material. Vonox Labs sells research-use-only compounds — not Vyleesi. The FDA approval applies to the approved drug product manufactured to pharmaceutical standards for a labeled indication. It does not make research-grade PT-141 a medicine, and the two must not be blurred.
• The FDA label for Vyleesi describes transient increases in blood pressure and decreases in heart rate, and the product is not for use in patients with uncontrolled hypertension or known cardiovascular disease — label facts underscoring that the approved product and research material are different categories.
• No male indication was ever approved. The intranasal PT-141 erectile-dysfunction program was discontinued; there is no approved PT-141 product for men.
• Athletes should check current anti-doping rules, as peptide categories are broad and updated regularly.

What Does the Research Say?

The PT-141 literature provides the melanocortin field’s strongest clinical evidence — the RECONNECT trials are large, randomized, and published — but the limitations are real:

First, the effect sizes in RECONNECT, while statistically significant, are numerically modest — a 0.30–0.42 point separation on a desire-domain scale: a measurable shift on self-reported questionnaires, not a large or transformative effect.

Second, the trial population was narrow: premenopausal women, mean age 39, predominantly white and US-based. Generalization beyond that population is unsupported.

Third, the male erectile-function literature is small and old — early-2000s intranasal studies — and the program was discontinued. No late-stage or long-term human evidence exists for PT-141 in men.

Fourth, most mechanistic evidence is preclinical. The central-MC4R model is well supported in animals, but the human neurobiology remains partially characterized.

Fifth, and most important here: FDA approval of Vyleesi is evidence about a pharmaceutical product, not about research-use material. It does not validate the identity, purity, or effects of any unregulated PT-141 product.

The published literature is modest in volume but high in quality at its peak — one indication is genuinely evidence-based, and everything else is exploratory.

Frequently Asked Questions

What is PT-141?

PT-141 is the development code for bremelanotide, a synthetic cyclic heptapeptide researched as a melanocortin-receptor agonist with preferential MC4R activity. Developed by Palatin Technologies from the Melanotan II research program, it was studied for sexual dysfunction — most notably in the Phase 3 RECONNECT trials in women with hypoactive sexual desire disorder.

What does the research show?

The RECONNECT Phase 3 trials (1,267 premenopausal women) reported statistically significant improvements in desire scores and reductions in distress versus placebo, with modest absolute effect sizes. Earlier small studies reported erectile responses to intranasal PT-141 in men — but the male program was discontinued without approval.

Is PT-141 FDA approved?

Bremelanotide — the same molecule — is FDA approved as the drug product Vyleesi (2019) for acquired, generalized HSDD in premenopausal women. However, research-use PT-141 material is not Vyleesi and is not an approved medicine; the approval applies only to the pharmaceutical product for its labeled indication.

How is PT-141 different from Melanotan II?

Both are cyclic heptapeptides from alpha-MSH research, but Melanotan II is a broad, non-selective agonist of four melanocortin receptors, while bremelanotide was engineered for narrower MC4R-preferential activity. Melanotan II was never approved for any indication; bremelanotide was approved as Vyleesi.

Has PT-141 been tested in men?

Yes, in small early-phase studies in the early 2000s using intranasal delivery, which reported erectile responses. The male development program was discontinued and no PT-141 product has been approved for men.

The Bottom Line

PT-141 (bremelanotide) is the melanocortin field’s flagship translation story — a cyclic heptapeptide MC4R agonist engineered from Melanotan II research that produced statistically significant results in two large Phase 3 trials and became the FDA-approved drug Vyleesi for premenopausal HSDD in 2019.

The clinical peak is real but narrow: modest effect sizes, a specific population, one indication. The male program ended without approval, the mechanistic literature is largely preclinical, and the FDA approval belongs to a pharmaceutical product — not to research-use material, which must never be confused with Vyleesi.

For researchers interested in central melanocortin pharmacology and how receptor science becomes an approved medicine, it remains the most instructive compound in the peptide literature.

Explore PT-141

Learn more about PT-141 and explore our research-focused PT-141 peptide at Vonox Labs: PT-141

Research. Test. Learn.

Research Use Only: Vonox Labs products are intended strictly for laboratory and research purposes and are not intended for human or veterinary consumption. This information is provided for educational purposes only and is not medical advice.

Scientific References

• Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908. PMID 31599840. (The RECONNECT trials: 1,267 premenopausal women, 24 weeks; statistically significant desire and distress improvements with modest absolute effect sizes.)
• Simon JA, Kingsberg SA, Portman D, Williams LA, Krop J, Lucas J, Clayton AH. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol. 2019;134(5):909-917. (52-week open-label extension of the RECONNECT program.)
• Clayton AH, Althof SE, Kingsberg SA, DeRogatis LR, Kroll R, Goldstein I, Kaminetsky J, Spana C, Lucas J, Jordan R, Portman DJ. Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial. Womens Health (Lond). 2016;12(3):325-337. (Phase 2b dose-finding trial preceding RECONNECT.)
• Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2004;16(1):51-59. (Early male program: significant erectile response at doses above 7 mg, onset ~30 minutes.)
• Diamond LE, Earle DC, Garcia WD, Spana C. Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response. Urology. 2005;65(4):755-759. (Central + peripheral combination: significantly greater erectile response versus sildenafil alone.)
• Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med. 2006;3(4):628-638. (Early female sexual-response study preceding the HSDD program.)
• Pfaus JG, Giuliano F, Gelez H. Bremelanotide: an overview of preclinical CNS effects on female sexual function. J Sex Med. 2007;4(Suppl 4):269-279. PMID 17958619. (Review of bremelanotide’s preclinical CNS effects on female sexual function.)
• Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102. (Early development-era overview of PT-141’s melanocortin pharmacology.)